RECRUITING

Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.

Official Title

Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm

Quick Facts

Study Start:2024-06-21

Study Completion:2028-08-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06474533

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:4 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Presence or suspicion of intracranial neoplasm in two populations: * Population 1: Participants after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on MRI. * Three sub-populations will be considered: * Recurrent metastatic lesions. * Recurrent high-grade gliomas (Grades 3 and 4). * Recurrent low-grade gliomas (Grade 2). * Population 2: Participants prior to primary treatment with planned biopsy or surgical resection. * Age \> 3 years.	* Participants with known incompatibility to PET or Computerized tomography (CT)/magnetic resonance imaging (MRI) scans. * Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation. * Sedation or anesthesia can be used for participants who cannot tolerate the exam.

Inclusion Criteria

Exclusion Criteria

* Presence or suspicion of intracranial neoplasm in two populations:
* Population 1: Participants after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on MRI.
* Three sub-populations will be considered:
* Recurrent metastatic lesions.
* Recurrent high-grade gliomas (Grades 3 and 4).
* Recurrent low-grade gliomas (Grade 2).
* Population 2: Participants prior to primary treatment with planned biopsy or surgical resection.
* Age \> 3 years.

* Participants with known incompatibility to PET or Computerized tomography (CT)/magnetic resonance imaging (MRI) scans.
* Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.
* Sedation or anesthesia can be used for participants who cannot tolerate the exam.

Contacts and Locations

Study Contact

Louise Magat

CONTACT

(415) 502-1822

Louise.Magat@ucsf.edu

Principal Investigator

Javier Villanueva-Meyer, MD

PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Study Locations (Sites)

University of California, San Francisco

San Francisco, California, 94143

United States

Collaborators and Investigators

Sponsor: Thomas Hope

Javier Villanueva-Meyer, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-21

Study Completion Date2028-08-31

Study Record Updates

Study Start Date2024-06-21

Study Completion Date2028-08-31

Terms related to this study

Additional Relevant MeSH Terms

Intracranial Neoplasm